Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Viracta Therapeutics, Inc./ 8-K

Current Report · 8-K

Viracta Therapeutics, Inc.

Current Report

Filed Nov 22, 2024Accepted Nov 22, 2024, 12:20 PM ESTCIK 1061027Accession 0000950170-24-130294
View company →Permanent SEC source ↗
Share

Company context

Historical securities (2)
VIRXNASDAQ · EQUITY · Historical · closed Feb 2, 2025VIRXOTC · EQUITY · Historical · closed Jul 16, 2025

Recent company filings

  1. 25-NSE - filed by Nasdaq Stock Market LLC regarding Viracta Therapeutics, Inc.Jul 10, 2025
  2. SCHEDULE 13G - filed by FORWARD VENTURES V LP regarding Viracta Therapeutics, Inc.Feb 14, 2025
  3. Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsFeb 5, 2025
  4. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingJan 31, 2025
  5. Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial ObligationJan 24, 2025